Senzar Asset Management LLC decreased its holdings in shares of Retrophin, Inc. (NASDAQ:RTRX) by 42.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 246,289 shares of the biopharmaceutical company’s stock after selling 183,900 shares during the quarter. Retrophin accounts for approximately 1.2% of Senzar Asset Management LLC’s investment portfolio, making the stock its 20th largest position. Senzar Asset Management LLC owned 0.65% of Retrophin worth $4,775,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of RTRX. SG Americas Securities LLC increased its stake in shares of Retrophin by 1.8% in the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 146 shares during the period. Legal & General Group Plc increased its stake in shares of Retrophin by 4.3% in the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 355 shares during the period. Weiss Multi Strategy Advisers LLC acquired a new position in shares of Retrophin in the first quarter valued at approximately $185,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Retrophin in the first quarter valued at approximately $219,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Retrophin in the second quarter valued at approximately $246,000.

Retrophin, Inc. (NASDAQ:RTRX) traded up 1.50% on Friday, hitting $23.04. The stock had a trading volume of 173,529 shares. Retrophin, Inc. has a 1-year low of $15.55 and a 1-year high of $25.11. The company has a 50-day moving average price of $22.97 and a 200-day moving average price of $19.66. The stock’s market capitalization is $884.39 million.

Retrophin (NASDAQ:RTRX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.10). The firm had revenue of $38.80 million during the quarter, compared to the consensus estimate of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.07 EPS. Equities analysts predict that Retrophin, Inc. will post ($1.13) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/24/retrophin-inc-rtrx-shares-sold-by-senzar-asset-management-llc.html.

Several research firms have recently issued reports on RTRX. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Retrophin currently has an average rating of “Buy” and an average target price of $32.33.

In related news, COO Neil F. Mcfarlane sold 1,378 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the sale, the chief operating officer now owns 13,622 shares in the company, valued at approximately $306,495. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.41% of the company’s stock.

Retrophin Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.